Perspective Therapeutics Files 8-K on Officer/Director Changes
Ticker: CATX · Form: 8-K · Filed: Sep 4, 2025 · CIK: 728387
Sentiment: neutral
Topics: officer-changes, director-changes, corporate-governance
TL;DR
Perspective Therapeutics is changing up its execs and board, filing an 8-K on 9/4.
AI Summary
Perspective Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting events as of September 2, 2025. The filing includes information regarding the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also contains Regulation FD disclosures and financial statements and exhibits.
Why It Matters
This 8-K filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key personnel and officer appointments can indicate internal shifts that may carry associated risks.
Key Numbers
- 001-33407 — SEC File Number (Identifier for Perspective Therapeutics, Inc.)
- 41-1458152 — IRS Employer Identification No. (Tax identification for Perspective Therapeutics, Inc.)
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Registrant
- Isoray, Inc. (company) — Former Company Name
- CENTURY PARK PICTURES CORP (company) — Former Company Name
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
When were the events reported in the 8-K effective?
The earliest event reported was as of September 2, 2025.
What is the filing date of this 8-K?
The 8-K was filed on September 4, 2025.
What is the primary business of Perspective Therapeutics, Inc.?
Perspective Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What other information is included in this filing besides personnel changes?
The filing also includes Regulation FD Disclosures and Financial Statements and Exhibits.
Filing Stats: 2,014 words · 8 min read · ~7 pages · Grade level 12.2 · Accepted 2025-09-04 07:04:41
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CATX NYSE American LLC
- $500,000 — k will receive an annual base salary of $500,000 and will be eligible for an annual bonu
Filing Documents
- catx-20250902.htm (8-K) — 66KB
- catx-ex99_1.htm (EX-99.1) — 20KB
- img236230851_0.jpg (GRAPHIC) — 41KB
- 0000728387-25-000013.txt ( ) — 258KB
- catx-20250902.xsd (EX-101.SCH) — 26KB
- catx-20250902_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 4, 2025, the Company issued a press release announcing the leadership transition described in Item 5.02 of this Form 8-K and related matters. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 4, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: September 4, 2025 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer